CHARLES SCHWAB INVESTMENT MANAGEMENT INC
Position in RXRX — Recursion Pharmaceuticals, Inc.
CIK 884546
SAN FRANCISCO, CA
Position in RXRX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$15,187,509
+$3,494,500 QoQ
Shares Held
4,138,286
+8.7% QoQ
Ownership
0.773%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#17
of 344 holders
Holding Since
Jun 2021
21 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RXRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CHARLES SCHWAB INVESTMENT MANAGEMENT INC holds $7,402,603,842 across 299 Biotechnology names. RXRX ranks #84 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,041,282 | $1,013,966,007 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
846,306 | $527,705,642 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
1,917,025 | $359,020,441 | |
| 4 | MRNA |
Moderna, Inc.
|
4,838,884 | $338,867,045 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
755,377 | $227,391,137 | |
| 6 | INCY |
Incyte Corp
|
1,692,439 | $191,854,884 | |
| 7 | RPRX |
Royalty Pharma plc
|
3,083,528 | $172,893,414 | |
| 8 | CYTK |
Cytokinetics Inc
|
1,565,781 | $133,388,883 |
All Filings in RXRX
Export CSV
21 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,187,509 | 4,138,286 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $11,693,009 | 3,808,798 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $16,338,122 | 3,994,651 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $16,811,697 | 3,445,020 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $13,101,362 | 2,589,202 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $12,052,741 | 2,278,401 | Shares | Sole | 2025-09-15 | |
| 2024-12-31 | $15,372,260 | 2,274,003 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $12,789,081 | 1,940,680 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $12,388,155 | 1,651,754 | Shares | Sole | 2024-08-12 | |
| 2024-03-31 | $12,093,729 | 1,213,012 | Shares | Sole | 2024-05-09 | |
| 2023-12-31 | $11,742,096 | 1,190,882 | Shares | Sole | 2024-02-06 | |
| 2023-09-30 | $8,858,439 | 1,157,966 | Shares | Sole | 2023-11-08 | |
| 2023-06-30 | $7,475,804 | 1,000,777 | Shares | Sole | 2023-08-10 | |
| 2023-03-31 | $6,562,873 | 983,939 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $7,591,890 | 984,681 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $9,623,922 | 904,504 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $3,486,703 | 428,342 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $2,671,854 | 373,164 | Shares | Sole | 2022-05-13 | |
| 2021-12-31 | $6,462,104 | 377,239 | Shares | Sole | 2022-02-11 | |
| 2021-09-30 | $4,205,583 | 182,772 | Shares | Sole | 2021-11-16 | |
| 2021-06-30 | $6,018,156 | 164,881 | Shares | Sole | 2021-08-16 | |
| No filing history on record for this holder in this stock. | ||||||